TP53 and cancer: Previous studies have demonstrated that in IDH1-mutant cancer cells, NAPRT is downregulated, resulting in hypersensitivity to NAD depletion through NAMPT inhibition, leading to AMPK activation and autophagy, as well as increases in reactive oxygen species, p53 activation and cell death [17,36].